NL-OMON48721已完成4 期
The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY ELLIPTA) when Compared with Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients within a Usual Care Setting.(study 206854) - study 206854
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Males and females *40 years of age.
- •* Documented diagnosis of COPD.
- •* COPD Assessment Test (CAT) *10 at screening.
- •* At least one moderate to severe exacerbation in the past 3 years.
- •* Continuous treatment for at least 60 days during the past 16 weeks with inhaled corticosteroid plus long-acting *2-agonist plus long-acting muscarinic antagonist or long-acting *2-agonist plus long-acting muscarinic antagonist or inhaled corticosteroid plus long-acting *2-agonist. In case of dual therapy: A documented indication for triple therapy must be present.
排除标准
- •* Woman of childbearing potential. See protocol page 27 for details.
- •* Unstable COPD. See protocol page 27 for details.
- •* Chronic use of oral corticosteroids. See protocol page 27 for details.
研究者
相似试验
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDEUCTR2017-004369-29-ESGlaxoSmithKline, S.A.3,000
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 21.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2017-004369-29-NLGlaxoSmithKline Research & Development Limited3,341
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855EUCTR2017-004369-29-GBGlaxoSmithKline Research & Development Limited3,000
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855EUCTR2017-004369-29-SEGlaxoSmithKline Research & Development Limited3,000
尚未招募
4 期
Efficacy and safety of Fluticasone furoate with montelukast vs Fluticasone furoate with Cetirizine in patients with allergic rhinitisCTRI/2023/10/059253SRM institute of science and technology